Corvus Pharmaceuticals (CRVS) announced that the IND application submitted by its partner in China, Angel Pharmaceuticals, has been approved by the Center for Drug Evaluation, CDE, of the China National Medical Products Administration, NMPA, to initiate a Phase 1b/2 clinical trial of soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize soquelitinib in greater China and is responsible for all expenses related to its development in China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Holds Annual Stockholders Meeting
- Corvus Pharmaceuticals Reports Promising Phase 1 Trial Results
- Corvus announces new interim data from Phase 1 trial of soquelitinib
- Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho
- Biotech Alert: Searches spiking for these stocks today